1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Russia Pharmaceuticals and Healthcare Report Q4 2016

Russia Pharmaceuticals and Healthcare Report Q4 2016

  • November 2016
  • -
  • Business Monitor International
  • -
  • 96 pages

Includes 3 FREE quarterly updates


BMI View:

Russia's healthcare market is in a precarious position due to a severe lack of funding and an escalating burden of disease. The country's economic recession will see further pressure placed on the population for provision of care. Amendments to Russia's pharmaceutical legislation will, however, favour domestically-produced medicines over foreign drugmakers and multinational drugmakers will be pressured to establish a domestic manufacturing presence to comply with related new regulations. Nonetheless, given its sheer market size and unmet potential, the country will remain attractive for investment by multinational pharmaceutical firms for long-term growth.

Headline Expenditure Projections

- Pharmaceuticals: RUB1.0trn (USD16.6bn) in 2015 to RUB1.2trn (USD17.9bn) in 2016; +18.2% in local currency terms and +8.1% in US dollar terms. Forecast unchanged from last quarter.

- Healthcare: RUB5.4trn (USD88.3bn) in 2015 to RUB5.7trn (USD85.3bn) in 2016; +5.7% in local currency terms and -3.4% in US dollar terms. Forecast unchanged from last quarter.

Table Of Contents

Russia Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Russia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Russia 2012-2020) 14
Healthcare Market Forecast 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Russia 2012-2020) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Russia 2012-2020) 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Russia 2012-2020) 20
Prescription Drug Market Forecast 21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Russia 2012-2020) 24
Patented Drug Market Forecast 25
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Russia 2012-2020) 28
Generic Drug Market Forecast 29
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Russia 2012-2020) 30
OTC Medicine Market Forecast 31
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Russia 2012-2020) 32
Pharmaceutical Trade Forecast 33
Table: Pharmaceutical Trade Data And Forecasts (Russia 2014-2020) 35
Table: Pharmaceutical Trade Data And Forecasts local currency (Russia 2014-2020) 35
Industry Risk/Reward Index 36
Central And Eastern Europe Risk/Reward Index - Q4 2016 36
Russia Risk/Reward Index 43
Rewards 43
Risks 44
Regulatory Review 45
Intellectual Property Issues 47
Pricing Regime 50
Reimbursement Regime 54
Market Overview 55
Healthcare Sector 56
Table: Healthcare Resources (Russia 2010-2015) 57
Table: Healthcare Personnel (Russia 2010-2015) 57
Table: Healthcare Activity (Russia 2010-2015) 58
Research and Development 58
Clinical Trials 59
Competitive Landscape 64
Research-Based Industry 65
Table: Recent Developments 66
Table: Multinational Market Activity 67
Generic Drugmakers 68
Table: Activity Of Russian Drugmakers Independent Of Multinational Investment 69
Pharmaceutical Retail Sector 70
Company Profile 72
Johnson and Johnson 72
Novartis 75
Pharmstandard 79
Veropharm 83
Demographic Forecast 85
Demographic Outlook 85
Table: Population Headline Indicators (Russia 1990-2025) 86
Table: Key Population Ratios (Russia 1990-2025) 86
Table: Urban/Rural Population and Life Expectancy (Russia 1990-2025) 87
Table: Population By Age Group (Russia 1990-2025) 87
Table: Population By Age Group % (Russia 1990-2025) 88
Glossary 90
Methodology 92
Pharmaceutical Expenditure Forecast Model 92
Healthcare Expenditure Forecast Model 92
Notes On Methodology 93
Risk/Reward Index Methodology 94
Index Overview 95
Table: Pharmaceutical Risk/Reward Index Indicators 95
Indicator Weightings 96

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.